We all have been warned about the potential risk that hormone therapy (ADT) can cause to our heart and vascular health. A report from Lancet Oncology confirmed that men with prostate cancer living in Sweden when on hormonal therapies significantly increase their risk for experiencing a thromboembolic disease event. […]
Obesity has been associated with a worse prostate cancer prognosis and increased levels of insulin are thought to mediate this effect. It has been established that hyperinsulinemia associates with higher levels of insulin receptors (IR) in prostate cancers and increased tumor growth. Men with prostate cancer who are put on androgen blockade (ADT) develop increased [...]
We have talked about it many times in past posts, the potential that many believe combination therapy can hold for better treatments for all cancers, including advanced prostate cancer. Combination therapy has made AIDS treatment as successful as it has become and it holds a similar promise for cancer treatment. An example of this potential [...]
I am attending the 2010 annual meeting of ASCO. There is a lot going on and a lot to see and learn. I am taking notes and will share information, but m schedule will not allow for regular posts until I return on Tuesday evening. Joel T Nowak, MA,MSW
The National Comprehensive Cancer Network (NCCN), a private organization which develops what has become the standard of care guidelines for clinical practice in oncology, has modified their guidelines to included sipuleucel-T (Provenge) as a part of its prostate cancer management guidelines. The guidelines specify Provenge as a category 1 treatment which is appropriate as salvage [...]